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OBJECTIVE—Diabetic nephropathy clusters in families, sug-
gesting that genetic factors play a role in its pathogenesis. We
investigated whether similar clustering exists for proliferative
retinopathy in families with two or more siblings with type 1
diabetes.
RESEARCH DESIGN AND METHODS—The FinnDiane Study
has characterized 20% (4,800 patients) of adults with type 1
diabetes in Finland. In 188 families, there were at least two
siblings with type 1 diabetes. Ophthalmic records were obtained
for 369 of 396 (93%) and fundus photographs for 251 of 369 (68%)
patients. Retinopathy was graded based on photographs and/or
repeated ophthalmic examinations using the Early Treatment of
Diabetic Retinopathy grading scale.
RESULTS—Mean age at onset of diabetes was 14.3  10.2 years,
and mean duration was 25.9  11.8 years. Proliferative retinop-
athy was found in 115 of 369 patients (31%). The familial risk of
proliferative retinopathy was estimated in 168 of 188 sibships,
adjusted for A1C, duration, and mean blood pressure. Prolifera-
tive retinopathy in the probands (48 of 168) was associated with
an increased risk (odds ratio 2.76 [95% CI 1.25- 6.11], P  0.01) of
proliferative retinopathy in the siblings of probands (61 of 182).
The heritability of proliferative retinopathy was h
2  0.52  0.31
(P  0.05).
CONCLUSIONS—We found a familial clustering of proliferative
retinopathy in patients with type 1 diabetes. The observation
cannot be accounted for by conventional risk factors, suggesting
a genetic component in the pathogenesis of proliferative retinop-
athy in type 1 diabetes. Diabetes 57:2176–2180, 2008
D
iabetic nephropathy and proliferative retinopa-
thy are severe microvascular complications of
diabetes. Diabetic nephropathy clusters in fam-
ilies, suggesting that genetic factors play a role
in the pathogenesis of this complication (1). However,
there is not yet evidence for a similar clustering of
proliferative retinopathy in families with type 1 diabetes.
After 20 years of diabetes, almost all patients with type
1 diabetes and 58% of patients with type 2 diabetes show
signs of retinopathy. When retinopathy worsens, severe
visual loss eventually threatens 5–10% of patients (2). The
most severe form of retinopathy is proliferative retinopa-
thy, and most of the patients with this complication will
become blind after 5–10 years without treatment (3). The
prevalence of proliferative retinopathy varies between 13
and 50% after 15–20 years of diabetes duration in patients
needing insulin (2,4).
The prevalence of any retinopathy is strongly related to
duration and glucose exposure (2,4). Furthermore, poor
glycemic control increases the incidence and progression
of retinopathy (5,6). Nevertheless, glycemic exposure
seems to explain only a part of the risk of proliferative
retinopathy (7). In patients with type 2 diabetes, high
blood pressure increases the incidence of retinopathy (8).
It is noteworthy that proliferative retinopathy is associated
with diabetic nephropathy, a complication that is at least
in part genetically determined (2). Such an association
suggests that familial factors may also contribute to the
development of proliferative retinopathy.
Therefore, the aim of this study was to elucidate
whether there is a familial clustering of proliferative
retinopathy in patients with longstanding type 1 diabetes
and to estimate the degree of familiality by calculating the
heritability of proliferative retinopathy.
RESEARCH DESIGN AND METHODS
The present study was undertaken as part of the ongoing FinnDiane Study
(Finnish Diabetic Nephropathy Study), a nationwide multicenter project with
the aim of identifying genetic and environmental risk factors for diabetic
complications in type 1 diabetes. The protocol is in accordance with the
Declaration of Helsinki and was approved by the ethics committee of the
Helsinki University Central Hospital.
The FinnDiane Study has, to date, recruited 4,800 patients with type 1
diabetes. All patients who visit any of the participating 92 hospitals and health
care centers are given an opportunity to take part in the FinnDiane Study. The
response rate has been 78% (9). Although FinnDiane is not a population-based
study in the strict sense, the distribution of the patients closely follows the
distribution of the general population in Finland. As a part of the baseline visit,
patients answered the question of whether any of their close relatives had type
1 diabetes, as deﬁned by having an age at onset of 40 years or less and insulin
treatment initiated within 1 year of the diagnosis. With these criteria, 188
families with at least two siblings with type 1 diabetes were found (Table 1).
All of the siblings were contacted, and those siblings who agreed to take part
signed a consent form and were characterized at a FinnDiane center. Data on
medication, cardiovascular status, diabetic complications, hypertension, and
cardiovascular disease were obtained using a standardized questionnaire,
which was completed by the patient’s attending physician. Blood pressure
was measured twice in the sitting position using a mercury sphygmomanom-
eter after a rest of at least 10 min. Anthropometric data, such as height and
weight, were recorded, and blood was drawn for the laboratory measure-
ments, including A1C.
We were able to obtain ophthalmic records for 369 of 396 (93%) patients.
Photographs were available for 251 of 369 (68%) of these patients, and records
of repeated fundus examinations performed by a specialist in ophthalmology
for 332 of 369 (90%) patients. Both were available for 217 of 369 (59%) patients.
Those patients with images available (68%) had been photographed on a
median of three separate occasions (interquartile range [IQR] 1–5). For 34 of
369 (9%) patients, the only source of information was the screening photo-
graphs taken at the local health canters. A diabetologist’s evaluation of the
fundi was the only source of information for only 3 of 369 (1%) of the patients,
all of whom had mild diabetic retinopathy. All available patient data were used
to score the severity and progression of retinopathy, a procedure handled by
an ophthalmologist unaware of the demographic data and the presence or
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(ETDRS) grading scale was used, where 10 represents no retinopathy; 61 and
upward, proliferative retinopathy; and 80, advanced retinopathy (10). Patients
without photographs were assigned a most probable estimate of ETDRS score
based on the descriptions of repeated fundus examinations. The eye with the
more severe retinopathy was used to deﬁne the severity of retinopathy of the
patient.
Patient’s nephropathy status was classiﬁed according to their urinary
albumin excretion rate (AER) in at least two of three overnight or 24-h urine
collections. Normal AER was deﬁned as an AER 20 g/min or AER 30
mg/24 h, microalbuminuria as an AER 20 and 200 g/min or 30 and 300
mg/24 h, macroalbuminuria as an AER 200 g/min or 300 mg/24 h, and
end-stage renal disease as when the patient required dialysis or renal
transplantation.
Statistical analysis. The siblings were ranked by age, and the oldest sibling
was designated as the proband of each sibship. There were four twin pairs
from four different families, and the sibling with the longest duration of
diabetes was chosen as the proband in these particular sibships. Two twin
pairs were monozygotic as determined by microsatellite markers (ABI MD-10
V2.5; Applied Biosystems, Foster City, CA).
Data are presented as means  SD for continuous, normally distributed
variables and median and IQR for non–normally distributed variables.
Means  SE are given for heritability estimates. Unadjusted intrafamilial
associations were estimated by calculating intraclass correlations (ICCs) for
sibpairs. The FCOR program of the SAGE software package (Case Western
Reserve University, Cleveland, OH) was used with a uniform weighting
scheme, giving equal weights for each sibship regardless of the number of
sibpairs within the sibships (11). The correlations between ordinal ETDRS
scores and nephropathy status were also calculated with the FCOR program
using the same weighting scheme. Mean differences in current age and
duration of diabetes between probands and siblings were calculated using a
linear mixed model (Table 2).
To study familial aggregation of proliferative retinopathy or any retinopa-
thy, three complementary analyses were used. First, the presence or absence
of proliferative retinopathy or any retinopathy in the proband was estimated
as a risk factor for the corresponding condition in the other siblings. The
familial risks were estimated with logistic regression models, adjusted for
conventional risk factors, and ﬁtted with generalized estimating equations
using exchangeable correlation structure to account for correlations within
sibships (12). Second, to measure the degree of concordance within sibships,
the ICC of durations of diabetes to the diagnosis of proliferative retinopathy
was calculated in the 29 sibships in which two siblings had proliferative
retinopathy (Fig. 1). Third, the heritability (h
2) of proliferative retinopathy was
estimated by a liability threshold model as implemented in the SOLAR
software (SOLAR, version 4.0.7; Southwest Foundation for Biomedical Re-
search, San Antonio, TX) with A1C, mean arterial pressure, sex, and duration
of diabetes as covariates. The liability threshold model is an extension of the
variance components model to dichotomous traits, such as proliferative
retinopathy (13). In the variance components model, the overall phenotypic
variation is partitioned into individual variance components due to polygenic
effects (multiple unmeasured genes under an additive variance), covariates
(e.g., duration, sex, A1C, and blood pressure), and random environmental
effects. The estimated h
2 is deﬁned as the ratio of the genetic variance
component to the residual phenotypic variance and is an estimate of the
TABLE 1
Structure of sibships
Siblings with type
1 diabetes in the
same family Families
Patients with type
1 diabetes
Ophthalmic data
available
Patients with proliferative
retinopathy
2 siblings 171 342 323 101
3 siblings 14 42 38 13
4 siblings 3 12 8 1
Total 188 396 369 115
TABLE 2
Clinical characteristics and concordance within sibships (intraclass correlations) for the siblings with type 1 diabetes
Variable n (396) Mean  SD Range ICC (95% CI)
Age at onset (years) 387 14.3  10.2 0.2–40.0 0.15 (0.02–0.21)
Duration of diabetes
at the latest
ophthalmic examination (years)
369 25.9  11.8 1.0–55.4 0.39 (0.26–0.45)
Difference of duration between
probands and siblings (years)
2.4  1.3*
Current age (years) 387 40.2  11.5 14.5–69.3 0.69 (0.61–0.73)
Age difference between proband
and siblings (years)
4.9  1.2*
A1C (%) 380 8.5  1.5 5.0–13.8 0.22 (0.09–0.29)
Systolic pressure (mmHg) 378 135  18 95–215 0.20 (0.07–0.27)
Diastolic pressure (mmHg) 378 80  9 50–113 0.10 (0.04 to 0.16)
MAP (mmHg) 378 100  12 72–140 0.18 (0.04–0.25)
BMI (kg/m
2) 354 25.3  3.9 16.2–43.0 0.21 (0.07–0.28)
Total cholesterol (mmol/l) 341 4.9  1.0 1.9–12.0 0.21 (0.06–0.30)
HDL cholesterol (mmol/l) 341 1.6  0.52 0.2–4.3 0.33 (0.18–0.40)
Current smoking 369 Yes 86 (23%) 0.15 (0.01–0.22)
No 83 (77%)
ETDRS score 169 40 (IQR 20–62)† 10–80 0.37 (0.24–0.43)
PDR Yes 115 (31%) 0.28 (0.14–0.35)
No 254 (69%)
Nephropathy status 328 Normoalbuminuria 202 (54%) 0.26 (0.06–0.36)
Microalbuminuria 51 (14%)
Macroalbuminuria 50 (14%)
End-stage renal disease 25 (7%)
Data are *SE or †median value (188 sibships, men/women 202/167) unless otherwise indicated. MAP, mean arterial pressure; PDR,
proliferative retinopathy.
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determined by a likelihood ratio test. All other statistical calculations except
the ICCs and the variance component models were performed with SPSS 15.0
(SPSS, Chicago, IL).
RESULTS
Table 1 depicts the structure of the sibships and the
availability of ophthalmic data. Table 2 shows the clinical
characteristics of the studied patients and unadjusted
ICCs within sibships. Mean age at onset of diabetes was
14.3  10.2 years. The ratio of men to women was 202:167,
and mean duration of diabetes was 25.9  11.8 years. The
patients’ highest ETDRS scores were achieved at a median
of 2.1 (IQR 10.4 to 1.0) years before the FinnDiane
baseline visit. A strong positive association was found
between the ETDRS score and the nephropathy status
(r  0.63, P  0.001), which was available for 328 patients.
Proliferative retinopathy was found in 115 of 369 pa-
tients (31.1% [95% CI 26.4–35.9]). In 8 of 115 (7.0%)
patients, proliferative retinopathy was discovered at their
ﬁrst examination by an ophthalmologist. Thus, there were
no available reference points for these patients without
proliferative retinopathy. The other patients (n  107) had
all had at least one ophthalmic examination at a median of
1.0 (IQR 2.2 to 0.4) years before the diagnosis. Detailed
records of treatment and follow-up were available for each
patient with proliferative retinopathy. Mean duration from
onset of diabetes to proliferative retinopathy was 20.9 
7.5 years.
The familial risk of proliferative retinopathy was esti-
mated in 182 siblings of 168 probands. Siblings of pro-
bands with proliferative retinopathy had higher
unadjusted risk of proliferative retinopathy (odds ratio
[OR] 4.07 [95% CI 2.06–8.07], P  0.001) when compared
with siblings of probands without proliferative retinopa-
thy. When adjusted for duration of diabetes, A1C, and
mean arterial pressure, proliferative retinopathy in the
probands (48 of 168) remained a signiﬁcant risk factor
(2.76 [1.25–6.11], P  0.01) for the corresponding condi-
tion in the siblings (61 of 182) (Table 3). In contrast, the
absence of any retinopathy in the probands (37 of 168) was
not associated with absence of any retinopathy in the
siblings (39 of 182) of the probands (2.0 [0.82–5.10], P 
0.13). The absence of any retinopathy was associated with
lower A1C (0.77 [0.59–0.99], P  0.04) and shorter dura-
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FIG. 1. Concordance within sibship (ICC) of survival time without proliferative retinopathy in the 29 sibpairs in which both members had
proliferative retinopathy (ICC 0.47 [95% CI 0.14–0.71], P  0.004).
TABLE 3
Familial risk of proliferative retinopathy
Variable OR (95% CI) B (SE) P value
PDR status of proband (yes/no) 2.76 (1.25–6.11) 1.02 (0.40) 0.01
MAP (mmHg) 1.03 (0.99–1.06) 0.02 (0.17) 0.15
A1C (%) 1.33 (1.03–1.73) 0.29 (0.14) 0.03
Duration of diabetes (years) 1.13 (1.08–1.17) 0.12 (0.02) 0.001
Men 1.12 (0.51–2.45) 0.12 (0.40) 0.8
The presence of proliferative retinopathy in the proband was used as risk factor for proliferative retinopathy in 182 siblings of 168 probands
in a logistic regression analysis. MAP, mean arterial blood pressure; PDR, proliferative diabetic retinopathy.
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2178 DIABETES, VOL. 57, AUGUST 2008tion of diabetes (0.85 [0.78–0.92], P  0.001) but not with
blood pressure (1.1 [0.98–1.06], P  0.30) or sex (0.96
[0.36–2.53], P  0.93).
The 29 proband-sibling pairs in which both members
had proliferative retinopathy were concordant for the
survival time without proliferative retinopathy (ICC 0.47
[0.14–0.71], P  0.004) (Fig. 1). Despite a slightly shorter
duration of diabetes (25.0  11.8 vs. 26.8  11.9 years, P 
0.15), the younger siblings had a higher prevalence of
proliferative retinopathy (34.4% [66 of 192] vs. 27.7% [49 of
177], P  0.17) and often had a shorter duration between
developing diabetes and developing proliferative retinop-
athy (20.2  7.0 vs. 21.7  8.0 years, P  0.17) (Fig. 1). To
make sure these trends did not bias the estimates of
familial risk, we further calculated the risk of proliferative
retinopathy by either designating the probands randomly
(2.88 [1.32–6.27], P  0.01) or designating the siblings with
the longest duration as probands (2.48 [1.02–6.04], P 
0.04). Thus, the selection of the oldest sibling as proband
does not seem to produce a signiﬁcant bias to the estimate
of familial risk.
The heritability of proliferative retinopathy was h
2 
0.52  0.31 (P  0.05) in a sample of 362 of 396 patients.
The sex of the patient was left out from the variance
component model as being nonsigniﬁcant (P  0.1). The
proportion of variance attributable to all covariates (A1C,
duration, and blood pressure) was 0.23 (Kullback-Leibler
R
2).
DISCUSSION
This study shows an increased risk (OR 2.76 [95% CI
1.25–6.11], P  0.01) of proliferative retinopathy in sib-
lings of probands with proliferative retinopathy in type 1
diabetes. Such a familial clustering was supported by the
estimated heritability of proliferative retinopathy h
2 
0.52  0.31 (P  0.05). Notably, this degree of familiality is
similar to the previously reported clustering for diabetic
nephropathy in type 1 patients and suggests that genes
may play a major role also for the development of severe
retinopathy. In previous studies regarding diabetic ne-
phropathy, 50% of the risk could not be attributed to the
familial clustering of conventional risk factors (14). Simi-
larly, genetic risk factors may explain 50% of the risk of
proliferative retinopathy.
Diabetic retinopathy continues to progress even after
improvement of glycemic control (5,15). The more severe
the retinopathy is, the longer the delay before a beneﬁcial
effect of improved glycemic control is observed (5). Thus,
retinopathy appears to have an inherent momentum of
progression that by time leads to an almost linear increase
in the incidence of proliferative retinopathy (2). Further
proof of familiality is the conspicuous concordance of the
survival times within sibships (Fig. 1). Taken together, these
ﬁndings may be consistent with an altered expression of
one or more critical genes induced by hyperglycemia.
Previous studies have been able to show familial clus-
tering of severe nonproliferative retinopathy in families
with type 2 diabetes (16,17) and in families with a mixture
of both type 1 and type 2 patients (18). However, no
studies thus far have given estimates for the familial risk of
proliferative retinopathy. Despite the familiality of nonpro-
liferative retinopathy, attempts to ﬁnd evidence for an
involvement of any major loci in diabetic retinopathy have
turned out inconclusive. Three genome-wide scans have
offered suggestive evidence of linkage, though on a num-
ber of different chromosomes in patients with type 2
diabetes (19–21). The associations to various biologically
relevant candidate genes have been extraordinarily difﬁ-
cult to replicate (22). Such results are typical for multifac-
torial diseases with only a moderate familiality. The
genetic component of diabetic retinopathy is likely to be
polygenic and does not exclude the importance of inter-
acting environmental risk factors in the determination of
the ultimate risk. Some environmental risk factors such as
blood pressure and A1C also appear to be determined at
least in part by genetic factors. In this study, a single A1C
measurement was a signiﬁcant risk factor in both the
logistic regression analysis and the heritability calculation
despite the patients’ highest ETDRS scores occurring at a
median of 2.1 (IQR 10.4 to 1.0) years before the date of
the A1C measurement in the FinnDiane Study. This could
be a reﬂection of the predictive value of biological, be-
tween-individual variations in A1C, distinct from the mean
blood glucose (23). In fact, it has been noted that a single
A1C measurement offers a fair estimate of the glycemic
control during the previous 10 years (24). Another signif-
icant risk factor in this study was blood pressure. In-
creased blood pressure is considered to be a multifactorial
trait with an estimated genetic contribution in the range of
30–50% (25). The present study may be limited by the fact
that the longitudinal changes in these risk factors could
not be recorded, leaving possible residual intrafamilial
correlations unaccounted for. However, it has been shown
in a simulation study that familial clustering of two addi-
tive environmental risk factors only leads to a slight
excess in the clustering of a disease among the siblings
(26). Therefore, it is unlikely that the degree of familiality
observed here is the result of familial clustering of glyce-
mic control and blood pressure alone.
Microalbuminuria is a known predictor for the develop-
ment of proliferative retinopathy in patients with type 1
diabetes (27). There is controversy as to whether this
association is due to hyperglycemia or whether nephrop-
athy is truly an independent risk factor for proliferative
retinopathy. It has been observed that after renal trans-
plantation or initiation of dialysis, visual function stabi-
lizes (28). The stabilization could also be due to other
factors, such as lower blood pressure during renal replace-
ment therapy (29). A strong positive association between
the severity of retinopathy and the severity of nephropathy
was noted in this study (r  0.63, P  0.001), which
supports the hypothesis that there are common predispos-
ing factors behind these two microvascular complications.
Retinal photography has been reported to be the most
sensitive screening method for diabetic retinopathy. The
sensitivity is in excess of 80% in detecting proliferative
retinopathy (30). Ophthalmoscopy has less sensitivity but,
conversely, higher speciﬁcity. It provides good results in
the hands of trained professionals such as ophthalmolo-
gists and diabetologists (30). A high percentage of patients
with diabetes in Finland are undergoing regular fundus
photography. The national guidelines for the screening of
diabetic retinopathy were already published in 1992 and
updated in 2006 (31) emphasizing fundus photography as
the preferable screening method (32). The majority of the
patients in this study had attended several screening
examinations. Many were examined and treated by oph-
thalmologists, and eventually 68% had fundus photographs
available. Even with these repeated examinations, the
absence or presence of any retinopathy was not found to
cluster within families. This could reﬂect the fact that
K. HIETALA AND ASSOCIATES
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diabetes will eventually develop some degree of retinopa-
thy, thus making the detection of familial clustering more
difﬁcult.
The FinnDiane Study is not by deﬁnition a population-
based study, which may limit the generalizability of the
results. However, selection bias is unlikely because the
geographic distribution of FinnDiane patients closely fol-
lows the distribution of the genetically homogeneous
general population and also because we could obtain as
much as 93% of the ophthalmic data in the sibships.
Furthermore, the treatment of diabetes and its complica-
tions is fairly uniform across Finland. The prevalence of
proliferative retinopathy in this study (31.1% [95% CI
26.4–35.9]) corresponds to the prevalence (32.1% [29.2–
35.0]) in an independent sample of 1,001 patients with a
24.2  11.7 duration of diabetes in the FinnDiane Study
and to the prevalence (37.5% [34.6–40.4]) in a previous
population-based study of type 1 diabetes patients with
similar duration of diabetes in Finland (33).
In conclusion, this study found a familial clustering of
proliferative retinopathy in patients with type 1 diabetes
that cannot be accounted for by conventional risk factors.
This suggests a signiﬁcant genetic component in the
pathogenesis of proliferative retinopathy.
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